drugset / Trial / NCT05122650
A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP385 in the treatment of adult participants with moderate to severe ET.
Timeline
- Start
- 2021-12-06
- Primary completion
- 2024-05-30
- Completion
- 2024-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Suvecaltamide | Small molecule | 10 mg | Oral |
| Subject | Suvecaltamide | Small molecule | 20 mg | Oral |
| Subject | Suvecaltamide | Small molecule | 30 mg | Oral |